PDSB's cash position declined significantly from $41.7M to $26.7M while advancing multiple Phase 2/3 clinical trials, raising concerns about funding runway for their pipeline progression.
The company burned through approximately $15M in cash over the year while operating cash flow improved modestly to -$27.8M, suggesting continued high cash consumption despite some expense management. With only $26.7M remaining and ongoing Phase 3 trials, PDSB will likely need additional financing within the next 12-18 months to sustain operations.
PDSB's financial position weakened materially with total assets declining 33% to $30.5M, driven primarily by the substantial cash burn. Operating cash flow improved modestly and R&D expenses decreased 16% to $19.0M, indicating some cost discipline, but the company continues burning significant cash. The reduction in current liabilities by 45% suggests improved working capital management, though this doesn't offset the concerning depletion of the cash runway.
Current liabilities reduced — improved short-term financial position and working capital health.
Current assets declined 37.3% — monitor working capital adequacy and short-term liquidity.
Cash declined 35.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Total assets contracted 32.8% — asset sales, write-downs, or balance sheet optimization underway.
Operating cash flow grew 20.8% — strong conversion of earnings to cash, healthy business fundamentals.
Liabilities reduced 19.4% — deleveraging improves balance sheet strength and financial flexibility.
R&D spending cut 15.7% — could signal cost discipline or concerning reduction in innovation investment.
Operating income improving — cost discipline or growing revenue base absorbing fixed costs.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →